You are here

Article Text

Article menu
Download PDFPDF
Late Breaking Abstracts
01. Cervical Cancer
#950 SUCCOR 10 years: vision a decade after radical surgery as primary treatment for cervical cancer
  1. Nabil Manzour1,
  2. Luis Chiva2,
  3. Capîlna Mihai Emil3,
  4. Constantijne H Mom4,
  5. Lukasz Klasa5,
  6. Octavio Arencibia6,
  7. Mario Malzoni7,
  8. Robert Poka8,
  9. Fabrice Narducci9,
  10. Imre Pete10,
  11. Mariana Tavares11,
  12. Dimitrios Tsolakidis12,
  13. Dmytro Golub13,
  14. Margarida Bernardino14,
  15. Igor Berlev15,
  16. Goran Vujic16,
  17. Pierandrea De Iaco17,
  18. Marcin Jedryka18,
  19. Nerea Martin-Calvo19,
  20. Jose Angel Minguez1,
  21. The SUCCOR Study Group The Succor Study Group1
  1. 1Clínica Universidad de Navarra, Pamplona, Spain
  2. 2Clínica Universidad de Navarra, Madrid, Spain
  3. 3Emergency County Hospital, Targu Mures, Romania
  4. 4Amsterdam University Medical Centre, Amsterdam, The Netherlands
  5. 5University Clinical Centre, Gdansk, Poland
  6. 6University Maternal Hospital Canary Islands, Las Palmas, Spain
  7. 7Endoscopica Malzoni, Center for Advanced Endoscopic Gynecologic Surgery, Center for Advanced Endoscopic Gynecologic Surgery, Avellino, Italy
  8. 8Obstetrics and Gynecology; Unit of Gynecologic Oncology; Institute of Obstetrics and Gynecology; Faculty of Medicine, University of Debrecen, Debrecen, Hungary
  9. 9Department of Gynecology, Centre Oscar Lambret, Lille, France
  10. 10National Institute of Oncology, Budapest, Hungary
  11. 11IPO-PORTO, Porto, Portugal
  12. 12General Hospital of Thessaloniki Papageorgiou, Thessaloniki, Greece
  13. 13LISOD – Israeli Oncological Hospital, Kyiv, Ukraine
  14. 14Instituto Português de Oncologia de Lisboa, Lisboa, Portugal
  15. 15North-Western State Medical University. N.N. Petrov Research Institute of Oncology, St Petersburg, Russia
  16. 16Clinical Hospital Center, Zagreb, Croatia
  17. 17S.Orsola Hospital, Bologna, Italy
  18. 18Oncological Gynecology, Lower Silesian Cancer Center, Wroclaw, Poland
  19. 19Department of Preventive Medicine and Public Health, Universidad de Navarra, Pamplona, Spain

Abstract

Introduction/Background The SUCCOR study initially reported relevant findings in 2020 from a large European international study with a 5-year follow-up. Now, we offer an update, extending the analysis to a 10-year follow-up, addressing gaps in limited information about prolonged outcomes for this disease.

Methodology Contacting SUCCOR database authors, we requested data updates for 1272 patients. We dispatched a Case Report Form (CRF) to researchers from 126 institutions across 29 European countries. Our focus included tracking late recurrences and monitoring relapsed patients‘ progression, leading to a meticulous update of the 10-year follow-up for all participants.

Results The long-term analysis of 556 patients demonstrated an 8.81% relapse rate over a median 102-month follow-up. The 10-year overall survival stood at 91%, a decrease from 97% at the 5-year mark. Similarly, disease-free survival reached 90%, slightly lower than the 93% observed at 5 years. The data indicated that 77% of relapses occurred within the initial five years, highlighting a 3.22 relative risk for relapsing pre-5 years compared to post-5 years.

Regarding relapse locations, 55% occurred locally within five years, and after 5 years, 45.5% experienced local recurrences. No significant differences were found between the two groups. Patients with recurrences faced a 24-fold higher mortality risk (OR 23.7, 95%CI 11.4-47.8, p<0.001). The 2-year survival post-recurrence was 69% for those relapsing before 5 years and 80% after 5 years. However, during the last follow-up, 45% of patients with pre-5-year relapses were still alive, compared to 72% in the post-5-year relapse group over a median 34-month follow-up.

Conclusion In the Succor study, the 10-year overall survival and disease-free survival after radical hysterectomy for cervical cancer were 91% and 90%, respectively. Patients facing recurrence had a 24-fold higher risk of death. Notably, 77% of recurrences appeared within the initial 5 years, while 45% of relapsed patients remained alive after 34-months of follow-up

Disclosures Nothing to disclose.

https://doi.org/10.1136/ijgc-2024-ESGO.1114

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.